Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target Stay Ahead of the Market:Discover outperforming stocks and invest ...

Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...